Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2010.04547.x/abstract

Transient elastography and biomarkers for liver fibrosis assessment and

follow-up of inactive hepatitis B carriers

L. Castéra1,2, P.-H. Bernard2, B. Le Bail3, J. Foucher1,2, P. Trimoulet4, W.

Merrouche1, P. Couzigou1, V. de Lédinghen1Article first

published online: 23 DEC 2010

DOI: 10.1111/j.1365-2036.2010.04547.x

© 2010 Blackwell Publishing Ltd

Issue

Alimentary Pharmacology & Therapeutics

Volume 33, Issue 4, pages 455–465, February 2011

Summary

Background  Non invasive methods for fibrosis evaluation remain to be

validated longitudinally in hepatitis B.

Aim  To evaluate longitudinally transient elastography (TE) and biomarkers for

liver fibrosis assessment and follow-up of hepatitis B virus (HBV) inactive

carriers.

Methods  Three hundred and twenty-nine consecutive HBeAg-negative HBV patients

(201 inactive carriers) who underwent TE, Fibrotest and aspartate to platelet

ratio index (APRI) the same day were studied.

Results  TE (median 4.8 vs. 6.8 kPa, P < 0.0001), Fibrotest (0.16 vs. 0.35, P

< 0.0001) and APRI values (0.28 vs. 0.43, P < 0.0001) were significantly lower

in inactive carriers than in the remaining patients whereas they did not differ

among inactive carriers according to HBV DNA levels. In 82 inactive carriers

with repeated examinations, although differences were observed among individual

patients, TE values did not differ significantly over time (median intra-patient

changes at end of follow-up relative to baseline: −0.2 kPa, P = 0.12).

Conversely, significant fluctuations were observed for Fibrotest (+0.03, P =

0.012) and APRI (−0.01, P < 0.05). Eleven inactive carriers (5.5%) had initial

elevated TE values (>7.2 kPa) confirmed during follow-up in two with significant

fibrosis (F2 and F3) on liver biopsy.

Conclusion  Non-invasive tools, particularly TE, could be useful, in addition

to HBV DNA and transaminase levels, for follow-up of HBV inactive carriers as

well as better selection of patients who require a liver biopsy.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2010.04547.x/abstract

Transient elastography and biomarkers for liver fibrosis assessment and

follow-up of inactive hepatitis B carriers

L. Castéra1,2, P.-H. Bernard2, B. Le Bail3, J. Foucher1,2, P. Trimoulet4, W.

Merrouche1, P. Couzigou1, V. de Lédinghen1Article first

published online: 23 DEC 2010

DOI: 10.1111/j.1365-2036.2010.04547.x

© 2010 Blackwell Publishing Ltd

Issue

Alimentary Pharmacology & Therapeutics

Volume 33, Issue 4, pages 455–465, February 2011

Summary

Background  Non invasive methods for fibrosis evaluation remain to be

validated longitudinally in hepatitis B.

Aim  To evaluate longitudinally transient elastography (TE) and biomarkers for

liver fibrosis assessment and follow-up of hepatitis B virus (HBV) inactive

carriers.

Methods  Three hundred and twenty-nine consecutive HBeAg-negative HBV patients

(201 inactive carriers) who underwent TE, Fibrotest and aspartate to platelet

ratio index (APRI) the same day were studied.

Results  TE (median 4.8 vs. 6.8 kPa, P < 0.0001), Fibrotest (0.16 vs. 0.35, P

< 0.0001) and APRI values (0.28 vs. 0.43, P < 0.0001) were significantly lower

in inactive carriers than in the remaining patients whereas they did not differ

among inactive carriers according to HBV DNA levels. In 82 inactive carriers

with repeated examinations, although differences were observed among individual

patients, TE values did not differ significantly over time (median intra-patient

changes at end of follow-up relative to baseline: −0.2 kPa, P = 0.12).

Conversely, significant fluctuations were observed for Fibrotest (+0.03, P =

0.012) and APRI (−0.01, P < 0.05). Eleven inactive carriers (5.5%) had initial

elevated TE values (>7.2 kPa) confirmed during follow-up in two with significant

fibrosis (F2 and F3) on liver biopsy.

Conclusion  Non-invasive tools, particularly TE, could be useful, in addition

to HBV DNA and transaminase levels, for follow-up of HBV inactive carriers as

well as better selection of patients who require a liver biopsy.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2010.04547.x/abstract

Transient elastography and biomarkers for liver fibrosis assessment and

follow-up of inactive hepatitis B carriers

L. Castéra1,2, P.-H. Bernard2, B. Le Bail3, J. Foucher1,2, P. Trimoulet4, W.

Merrouche1, P. Couzigou1, V. de Lédinghen1Article first

published online: 23 DEC 2010

DOI: 10.1111/j.1365-2036.2010.04547.x

© 2010 Blackwell Publishing Ltd

Issue

Alimentary Pharmacology & Therapeutics

Volume 33, Issue 4, pages 455–465, February 2011

Summary

Background  Non invasive methods for fibrosis evaluation remain to be

validated longitudinally in hepatitis B.

Aim  To evaluate longitudinally transient elastography (TE) and biomarkers for

liver fibrosis assessment and follow-up of hepatitis B virus (HBV) inactive

carriers.

Methods  Three hundred and twenty-nine consecutive HBeAg-negative HBV patients

(201 inactive carriers) who underwent TE, Fibrotest and aspartate to platelet

ratio index (APRI) the same day were studied.

Results  TE (median 4.8 vs. 6.8 kPa, P < 0.0001), Fibrotest (0.16 vs. 0.35, P

< 0.0001) and APRI values (0.28 vs. 0.43, P < 0.0001) were significantly lower

in inactive carriers than in the remaining patients whereas they did not differ

among inactive carriers according to HBV DNA levels. In 82 inactive carriers

with repeated examinations, although differences were observed among individual

patients, TE values did not differ significantly over time (median intra-patient

changes at end of follow-up relative to baseline: −0.2 kPa, P = 0.12).

Conversely, significant fluctuations were observed for Fibrotest (+0.03, P =

0.012) and APRI (−0.01, P < 0.05). Eleven inactive carriers (5.5%) had initial

elevated TE values (>7.2 kPa) confirmed during follow-up in two with significant

fibrosis (F2 and F3) on liver biopsy.

Conclusion  Non-invasive tools, particularly TE, could be useful, in addition

to HBV DNA and transaminase levels, for follow-up of HBV inactive carriers as

well as better selection of patients who require a liver biopsy.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2010.04547.x/abstract

Transient elastography and biomarkers for liver fibrosis assessment and

follow-up of inactive hepatitis B carriers

L. Castéra1,2, P.-H. Bernard2, B. Le Bail3, J. Foucher1,2, P. Trimoulet4, W.

Merrouche1, P. Couzigou1, V. de Lédinghen1Article first

published online: 23 DEC 2010

DOI: 10.1111/j.1365-2036.2010.04547.x

© 2010 Blackwell Publishing Ltd

Issue

Alimentary Pharmacology & Therapeutics

Volume 33, Issue 4, pages 455–465, February 2011

Summary

Background  Non invasive methods for fibrosis evaluation remain to be

validated longitudinally in hepatitis B.

Aim  To evaluate longitudinally transient elastography (TE) and biomarkers for

liver fibrosis assessment and follow-up of hepatitis B virus (HBV) inactive

carriers.

Methods  Three hundred and twenty-nine consecutive HBeAg-negative HBV patients

(201 inactive carriers) who underwent TE, Fibrotest and aspartate to platelet

ratio index (APRI) the same day were studied.

Results  TE (median 4.8 vs. 6.8 kPa, P < 0.0001), Fibrotest (0.16 vs. 0.35, P

< 0.0001) and APRI values (0.28 vs. 0.43, P < 0.0001) were significantly lower

in inactive carriers than in the remaining patients whereas they did not differ

among inactive carriers according to HBV DNA levels. In 82 inactive carriers

with repeated examinations, although differences were observed among individual

patients, TE values did not differ significantly over time (median intra-patient

changes at end of follow-up relative to baseline: −0.2 kPa, P = 0.12).

Conversely, significant fluctuations were observed for Fibrotest (+0.03, P =

0.012) and APRI (−0.01, P < 0.05). Eleven inactive carriers (5.5%) had initial

elevated TE values (>7.2 kPa) confirmed during follow-up in two with significant

fibrosis (F2 and F3) on liver biopsy.

Conclusion  Non-invasive tools, particularly TE, could be useful, in addition

to HBV DNA and transaminase levels, for follow-up of HBV inactive carriers as

well as better selection of patients who require a liver biopsy.